Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Common Equity (2016 - 2025)

Kiora Pharmaceuticals' Common Equity history spans 11 years, with the latest figure at $16.1 million for Q4 2025.

  • For Q4 2025, Common Equity fell 37.4% year-over-year to $16.1 million; the TTM value through Dec 2025 reached $16.1 million, down 37.4%, while the annual FY2025 figure was $16.1 million, 37.4% down from the prior year.
  • Common Equity reached $16.1 million in Q4 2025 per KPRX's latest filing, down from $22.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $133.6 million in Q3 2021 to a low of $6.1 million in Q4 2023.
  • Average Common Equity over 5 years is $23.9 million, with a median of $16.0 million recorded in 2021.
  • Peak YoY movement for Common Equity: skyrocketed 2141.73% in 2021, then plummeted 92.13% in 2022.
  • A 5-year view of Common Equity shows it stood at $14.6 million in 2021, then decreased by 27.83% to $10.5 million in 2022, then tumbled by 41.93% to $6.1 million in 2023, then skyrocketed by 321.62% to $25.8 million in 2024, then crashed by 37.4% to $16.1 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Common Equity are $16.1 million (Q4 2025), $22.4 million (Q3 2025), and $22.1 million (Q2 2025).